Skip to main content
942-P: Caregivers of Children with Type 1 Diabetes Value Real-Time Functions of Continuous Glucose Monitoring.
1355-P: HbA1c Trajectories from Time of Diagnosis in Youth with T1D.
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
Decreasing Incidence of Postinsulin Hypoglycemia for Hyperkalemia Treatment.
Use of the Tidepool Platform to Collect, Integrate, and Visualize Diabetes Device Data in a Pediatric Clinic Setting.
Impact of Target HbA1c Change in Pediatric Participants in the T1D Exchange Clinic Registry.
Clinical Practice Factors That Define Insulin Pump Readiness.
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Recommendations for the definition of clinical responder in insulin preservation studies.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.